Follow us on Twitter
twitter icon@FreshPatents


Ocular Implant patents

      

This page is updated frequently with new Ocular Implant-related patent applications.




 Hypotensive lipid-containing biodegradable intraocular implants and related methods patent thumbnailHypotensive lipid-containing biodegradable intraocular implants and related methods
Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.
Allergan, Inc.


 Intracameral implant for treatment of an ocular condition patent thumbnailIntracameral implant for treatment of an ocular condition
The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise ocular implants having a desired extended drug release profile suitable for treating elevated intraocular pressure..
Envisia Therapeutics Inc.


 Intraocular implants and methods and kits therefor patent thumbnailIntraocular implants and methods and kits therefor
Devices, methods and kits are described for reducing intraocular pressure. The devices include a support that is implantable within schlemm's canal and maintains the patency of the canal without substantially interfering with transmural fluid flow across the canal.
Sight Sciences, Inc.


 Adjustable intraocular implant patent thumbnailAdjustable intraocular implant
Methods and devices for adjusting or configuring the flow rate of an intraocular shunt are provided whereby hypotony can be avoided by increasing the flow rate through the device. In some embodiments, the device is a shunt that can have a first flow that can be modified to a second flow by modifying the shunt, such as by cutting the shunt.
Aquesys, Inc.


 Ocular implants for delivery into an anterior chamber of the eye patent thumbnailOcular implants for delivery into an anterior chamber of the eye
An ocular implant adapted to be disposed within schlemm's canal of a human eye with a body extending along a curved longitudinal central axis in a curvature plane, a first strut on one side of the implant and a second strut on an opposite side of the implant, the circumferential extent of the first strut with respect to the plane of curvature being greater than the circumferential extent of the second strut with respect to the plane of curvature. The invention also includes methods of using the implant..

 Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods patent thumbnailOil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.
Allergan, Inc.


 Steroid-containing sustained release intraocular implants and related methods patent thumbnailSteroid-containing sustained release intraocular implants and related methods
Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants.
Allergan, Inc.


 Process for manufacturing an intraocular lens with an embedded mask patent thumbnailProcess for manufacturing an intraocular lens with an embedded mask
Intraocular implants and methods of making intraocular implants are provided. The intraocular implant can include a mask adapted to increase depth of focus.
Acufocus, Inc.


 Methods and devices for increasing aqueous humor outflow patent thumbnailMethods and devices for increasing aqueous humor outflow
An ocular implant having an inlet portion and a schlemm's canal portion distal to the inlet portion, the inlet portion being disposed at a proximal end of the implant and sized and configured to be placed within an anterior chamber of a human eye, the schlemm's canal portion being arranged and configured to be disposed within schlemm's canal of the eye when the inlet portion is disposed in the anterior chamber.. .

 Biodegradable ocular implant patent thumbnailBiodegradable ocular implant
Provided is a biodegradable ocular implant for sustained drug delivery, including a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein. A multi-layered biodegradable ocular implant is also disclosed..
Singapore Health Services Pte Ltd


Extraocular epiretinal implant

A visual prosthesis in the form of a retinal implant, which is distinguished by the least possible space requirement inside the eye, is achieved by a visual prosthesis having an intraocular implant and an extraocular implant, which supplies the intraocular implant with energy and controls it. Virtually all the electronic components, which do not necessarily need to be accommodated with the intraocular implant inside the eye, can be arranged outside the eyeball, for example on the sclera.
Pixium Vision Sa

Prostamide-containing intraocular implant

Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.. .
Allergan, Inc.

Biodegradable intravitreal tyrosine kinase implants

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol.
Allergan, Inc.

Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor

Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.. .
Allergan, Inc.

Ocular implant insertion apparatus and methods

An exemplary ocular implant insertion system includes a case and a preloaded ocular implant insertion apparatus. The apparatus includes first and second movable structures that move the ocular implant in a predetermined sequence.
Hoya Corporation

Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof

The invention provides new crystalline forms of 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid. This compound is commonly referred to as “bimatoprost acid.” the novel crystalline forms are designated forms i, ii, and iii.

Ocular implant delivery systems and methods

Described herein are delivery devices and methods of using the devices for delivering an ocular implant into a suprachoroidal space without use of a goniolens. The delivery device includes a handle including a channel extending from a proximal end of the handle to a distal end of the handle, an applier coupled to the handle, the applier including a blunt distal tip and an elongate, flexible wire insertable through a fluid channel of an ocular implant, and a fiber optic image bundle reversibly inserted through the channel such that the fiber optic image bundle extends to a region proximal to the blunt distal tip of the applier..

Ocular implant with therapeutic agents and methods thereof

Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye.

Ocular therapeutic agent delivery devices and methods for making and using such devices

ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described.
United States Of America, Department Of Health & Human Services, Represented By The Secretary, C/o

System and delivering multiple ocular implants

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye.
Glaukos Corporation

Composition for intraocular implantation of bevacizumab

A solid, compressed pharmaceutical composition comprises i) a peptide active pharmaceutical ingredient, ii) a polysaccharide excipient and/or an albumin, and iii) an oligosaccharide excipient. The polysaccharide excipient may be hyaluronic acid, or the potassium salt thereof, and the oligosaccharide excipient may be trehalose..
Ucl Business Plc

Delivery system for ocular implant

A delivery system is disclosed which can be used to deliver an ocular implant into a target location within the eye via an ab interno procedure. In some embodiments, the implant can provide fluid communication between the anterior chamber and the suprachoroidal or supraciliary space while in an implanted state.
Transcend Medical, Inc.

Reprogrammable tuneable liquid crystal lens intraocular implant and methods therefor

A reprogrammable intraocular adaptive lens prosthesis apparatus is provided. The apparatus includes a tunable liquid crystal lens (tlcl) encapsulated in the intraocular prosthesis with control electronics and a power source or in the intraocular prosthesis with a control signal receiver while an external control electronics package transmits the control signal.

Ocular system with anchoring implant and therapeutic agent

Ocular implants, delivery devices and methods for treating ocular disorders are disclosed. One method involves inserting an implant on one side of an eye.

Two-layer ocular implant

The present invention generally relates to local therapies for the eye and, more particularly, to shaped controlled-release ocular implant devices, including methods for making and using such devices, for delivery of therapeutic agents to the eye. A molded two-layer ocular implant comprises a therapeutic agent for treatment or prevention of a disorder of the eye.
Odin Biotech

In situ adjustable optical mask

Implantable corneal and intraocular implants such as a mask are provided. The mask can improve the vision of a patient, such as by being configured to increase the depth of focus of an eye of a patient.
Acufocus, Inc.

Intraocular cell migration inhibition system

Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye..
Insight Innovations, Llc

Ocular implant made by a double extrusion proces

The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end plga, and deliver active agents into an ocular region without a high burst release..
Allergan, Inc.

Ocular implants and methods for delivering ocular implants into the eye

An ocular implant is provided. In some embodiments, the ocular implant includes a body that is curved about a longitudinal central axis and a distal body portion that defines a longitudinal channel including a channel opening.

Sustained release intraocular implants and methods for treating ocular vasculopathies

Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.
Allergan, Inc.

Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye

Delivery devices, systems and methods are provided for inserting an implant into an eye. The delivery or inserter devices or systems can be used to dispose or implant an ocular stent or implant, such as a shunt, in communication with a suprachoroidal space of the eye.
Glaukos Corporation

Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof

Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.
Allergan, Inc.

Injectable combination therapy for eye disorders

The present invention provides composition, methods, and articles of manufacture for treating an eye disorder, e.g., a disorder characterized by macular degeneration, choroidal neovascularization, or retinal neovascularization. One method of the invention comprises the step of: administering first and second therapeutic agents to the subject's eye in a single procedure, wherein the first therapeutic agent provides rapid improvement in the condition of the subject's eye and the second therapeutic agent is administered as a sustained release formulation of the second therapeutic agent.
Potentia Pharmaceuticals, Inc.

Sustained release intraocular implants and methods for preventing retinal dysfunction

Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.
Allergan, Inc.



Ocular Implant topics:
  • Ocular Implant
  • Intraocular
  • Anterior Chamber
  • Ocular Implants
  • Intraocular Pressure
  • Anterior Chamber Of The Eye
  • Implantation
  • Biodegradable
  • Drug Delivery System
  • Bevacizumab
  • Medical Device
  • Multiple Stents
  • Aqueous Humor
  • Visualization
  • Instruments


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Ocular Implant for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Ocular Implant with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.6629

    file did exist - 2615

    0 - 1 - 52